Skip to main content
Signal8

Lunai Bioworks Inc. Form SCHEDULE 13D/A — Oct 15, 2026

Form SCHEDULE 13D/AFiled Oct 15, 2026, 9:13 PM ET0001214659-26-012970Original filing

William Anderson Wittekind filed Amendment No. 25 to his Schedule 13D on Lunai Bioworks Inc., reporting beneficial ownership of 226,665 shares, or 4.5% of the class. The amendment reflects shares outstanding of 5,034,452 as reported in the issuer's Form 10-K filed October 13, 2026; Wittekind no longer owns more than 5% of the company. His stake traces to the January 2018 merger among DanDrit BioTech USA, Renovaro Biopharma (then Enochian Biopharma), and his LLC Weird Science.

Key figures

Shares Owned
226665
Percent of class
4.5%
Sole voting power
70083
Shares outstanding
5034452
Shared voting power
156582

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.